Nikhil Prasad Fact checked by:Thailand Medical News Team Apr 03, 2026 1 hour, 47 minutes ago
Medical News: A growing body of scientific research is raising fresh concerns about the Epstein–Barr virus (EBV), a common but often overlooked infection now being reexamined in the wake of the COVID-19 pandemic. While EBV has long been known as the virus behind “mono” or glandular fever, new findings suggest its role in long-term illness, immune dysfunction, and even cancer may be far more significant than previously understood.
Scientists uncover how a common virus may drive long-term illness and cancer risks in the post-pandemic world
A Virus Almost Everyone Carries
EBV is one of the most widespread viruses in the world, with most people infected at some point in their lives, often during childhood. In many cases, it remains dormant inside the body without causing noticeable symptoms. However, under certain conditions, the virus can reactivate and trigger a wide range of health problems.
Scientists now believe that the global COVID-19 pandemic may have unintentionally changed how EBV behaves in the human body. Disruptions to immune systems, combined with widespread viral exposure, appear to have created new patterns of infection and reactivation that are only beginning to be understood.
Pandemic Effects Changed Infection Patterns
During lockdowns and periods of strict hygiene measures, fewer people - especially children - were exposed to EBV at an early age. This delay in initial infection may sound beneficial, but researchers warn it could lead to more severe symptoms later in life when infection eventually occurs.
At the same time, studies suggest that co-infection or interaction between SARS-CoV-2 and EBV may contribute to lingering symptoms often seen in long COVID patients. These include chronic fatigue, brain fog, and persistent inflammation.
Hidden Mechanisms Behind Reactivation
A key focus of recent research has been understanding how EBV switches between its inactive (latent) and active (lytic) states. Scientists have identified specific molecular “triggers” that control this process.
One important discovery involves small molecules called microRNAs, which act like switches that can turn viral activity on or off. Certain microRNAs appear to suppress EBV reactivation by targeting critical viral genes. When these controls fail, the virus can become active again, potentially leading to disease.
Other research highlights how EBV manipulates human cells at the genetic level. By interfering with normal gene expression, the virus can promote cell survival and growth - conditions that may contribute to cancer development, particularly in cases such as gastric cancer and nasopharyngeal carcinoma.
This
Medical News report highlights that EBV is not just a harmless “passenger” virus but a complex biological agent capable of influencing multiple systems in the body, especially when immune defenses are weakened or disrupted.
/>
Surprising and Rare Complications
Although many EBV infections are mild, doctors are increasingly reporting unusual and sometimes alarming complications. These include neurological issues such as temporary nerve paralysis and unexpected reactions to common medications.
In rare cases, patients with EBV-related cancers have developed severe skin reactions when treated with antibiotics like amoxicillin. These findings underscore how unpredictable the virus can be, particularly in individuals with underlying conditions.
Advances in Detection and Treatment
Encouragingly, researchers are making progress in how EBV is detected and treated. Traditional diagnostic methods relied on antibody testing, which could miss subtle or early-stage infections. Today, advanced molecular techniques allow for much more precise detection of viral activity in the body.
Perhaps most exciting is the development of cutting-edge therapies using gene-editing technology. Scientists are exploring the use of CRISPR systems to directly target and suppress EBV within infected cells. Early studies show that this approach can significantly reduce viral load, opening the door to new treatments that go beyond symptom management.
Institutions Behind the Research
The research discussed in this report was led by experts from the Department of Laboratory Medicine at The Third Affiliated Hospital of Southern Medical University and The Third School of Clinical Medicine, Southern Medical University, Guangzhou, China. Their work brings together contributions from multiple international studies focusing on virology, oncology, and immunology.
A New Era of Awareness and Urgency
The findings suggest that EBV should no longer be considered a minor or routine infection. Instead, it represents a significant and evolving health challenge, particularly in the context of post-pandemic immune changes.
Researchers emphasize that understanding EBV’s behavior is critical for addressing a wide range of modern health issues - from chronic fatigue syndromes to cancer. Public awareness, early detection, and continued scientific innovation will be key in managing its impact.
Conclusion
The post-COVID era has reshaped how scientists view long-standing viral infections like EBV. What was once considered a mostly harmless virus is now recognized as a potential contributor to complex and chronic diseases. The interplay between immune disruption, viral reactivation, and genetic manipulation highlights the need for deeper research and more proactive healthcare strategies. As new diagnostic tools and therapies emerge, there is cautious optimism that EBV-related diseases can be better controlled, but the urgency to act has never been greater.
The study findings were published in the peer reviewed journal: Viruses.
https://www.mdpi.com/1999-4915/18/4/427
For the latest on the EBV virus, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/coronavirus
https://www.thailandmedical.news/articles/long-covid
Share
Tweet
Share
